110 related articles for article (PubMed ID: 17329684)
1. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
[TBL] [Abstract][Full Text] [Related]
2. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
[TBL] [Abstract][Full Text] [Related]
3. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
[TBL] [Abstract][Full Text] [Related]
4. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
[TBL] [Abstract][Full Text] [Related]
5. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):448-55. PubMed ID: 12722742
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
7. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
9. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
10. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats.
Raatschen HJ; Simon GH; Fu Y; Sennino B; Shames DM; Wendland MF; McDonald DM; Brasch RC
Radiology; 2008 May; 247(2):391-9. PubMed ID: 18372448
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive quantification of anti-angiogenic therapy by contrast-enhanced MRI in experimental pancreatic cancer.
Raatschen HJ; Fischer S; Zsivcsec B; Schoenfeld CO; Hotz B; Buhr HJ; Hotz HG
Acta Radiol; 2014 Mar; 55(2):131-9. PubMed ID: 23892234
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice.
de Lussanet QG; Langereis S; Beets-Tan RG; van Genderen MH; Griffioen AW; van Engelshoven JM; Backes WH
Radiology; 2005 Apr; 235(1):65-72. PubMed ID: 15731376
[TBL] [Abstract][Full Text] [Related]
15. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.
Thoeny HC; De Keyzer F; Vandecaveye V; Chen F; Sun X; Bosmans H; Hermans R; Verbeken EK; Boesch C; Marchal G; Landuyt W; Ni Y
Radiology; 2005 Nov; 237(2):492-9. PubMed ID: 16192323
[TBL] [Abstract][Full Text] [Related]
16. [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].
Ran JT; Zhou YN; Tang CW; Lu JR; Wu J; Lu H; Yang GD
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):448-51. PubMed ID: 19024521
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
[TBL] [Abstract][Full Text] [Related]
18. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor.
Gossmann A; Helbich TH; Mesiano S; Shames DM; Wendland MF; Roberts TP; Ferrara N; Jaffe RB; Brasch RC
Am J Obstet Gynecol; 2000 Oct; 183(4):956-63. PubMed ID: 11035346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
